Abstract | Plasmacytoid dendritic cells (pDCs) are a unique DC subset that specializes in the production of type I interferons (IFNs). pDCs promote antiviral immune responses and have been implicated in the pathogenesis of autoimmune diseases that are characterized by a type I IFN signature. However, pDCs can also induce tolerogenic immune responses. In this Review, we summarize recent progress in the field of pDC biology, focusing on the molecular mechanisms that regulate the development and functions of pDCs, the pathways involved in their sensing of pathogens and endogenous nucleic acids, their functions at mucosal sites, and their roles in infection, autoimmunity and cancer.
Plasmacytoid dendritic cells (pDCs) were originally described in human lymph nodes in the 1950s
1 . These cells were later found to secrete high amounts of type I interferons (IFNs) in response to viruses 2,3 , thereby corresponding to the enigmatic natural IFNproducing cells that had previously been identified in human peripheral blood 4, 5 . pDCs specialize in producing type I IFNs following their recognition of viruses or self nucleic acids through Toll-like receptor 7 (TLR7) and TLR9 . However, pDCs can also secrete other pro-inflammatory cytokines and chemokines, including interleukin-6 (IL-6), IL-12, CXC-chemokine ligand 8 (CXCL8), CXCL10, CC-chemokine ligand 3 (CCL3) and CCL4. Moreover, expression of MHC class II and co-stimulatory molecules enables pDCs to present antigens to CD4 + T cells. Thus, the biology of pDCs is multifaceted (FIG. 1) .
The identification of pDCs in mice in 2001 (REFS 9-11) has bolstered research in the pDC field, permitting the exploration of the mechanisms involved in their develop ment and their roles in innate and adaptive immunity. In addition to contributing to innate antiviral immunity, pDCs can participate in the priming of both immunogenic and tolerogenic adaptive immune responses. Human pDCs also continue to be extensively studied with a view to understanding their potential roles in the pathogenesis of autoimmune diseases, cancer and HIV infection. In this Review, we discuss the recent progress that has been made in these areas of mouse and human pDC biology. We begin by discussing the pheno type of pDCs and the mechanisms that control their development.
Phenotypes of human and mouse pDCs
Human pDCs lack expression of the lineage-associated markers CD3, CD19, CD14, CD16 and CD11c, and they selectively express the C-type lectin BDCA2 (also known as CLEC4C) and the immunoglobulin super family receptor immunoglobulin-like transcript 7 (ILT7; also known as LILRA4) 12 . Human pDCs also express CD4, CD68 (also known as macrosialin), ILT3 (also known as LILRB4) and the IL-3 receptor α-subunit (also known as CD123). Accordingly, IL-3 mediates human pDC survival in vitro 3 . CD2 is a cell adhesion molecule that is expressed by a subset of human pDCs 13 . CD2 hi pDCs produce lysozyme, but whether this endows them with the capacity to lyse bacteria is unknown. The markers most commonly used to identify pDCs in mice are CD11c, B220, LY6C, bone marrow stromal antigen 2 (BST2; also known as tetherin 14 ) and sialic acid-binding immunoglobulin-like lectin H (Siglec-H). In contrast to human pDCs, which are CD11c -, mouse pDCs express intermediate levels of CD11c. BST2 is fairly specific to pDCs and plasma cells in steady-state conditions but is induced on many cell types following exposure to type I and type II IFNs 15 . In cell suspensions from primary and secondary lymphoid organs, Siglec-H expression is mainly confined to pDCs 16, 17 and is downregulated upon activation 18 . However, specialized macrophage subsets in the spleen, lymph nodes and brain also express Siglec-H 17, 19 . In addition, studies in reporter mice have confirmed Siglech mRNA transcription in progenitor cells 18, 20, 21 . Mouse pDCs can also express CD8α and, similarly to human pDCs, CD4. In peripheral tissues, the majority of mouse pDCs express CC-chemokine receptor 9 (CCR9), LY49Q (also known as KLRA17) and SCA1; however, in the bone marrow, these markers distinguish pDC subsets that differ in terms of their developmental stage and/or activation state
.
Development of pDCs Progenitors and cytokines required for pDC development.
A common DC progenitor (CDP) that generates both pDCs and classical DCs (cDCs), but not other cell lineages, has been identified in the bone marrow. The CDP is characterized by lack of lineage markers (LIN -) and by the expression of Fms-like tyrosine kinase 3 (FLT3; also known as CD135), macrophage colony-stimulating factor receptor (M-CSFR; also known as CD115 and CSF1R) and the receptor tyrosine kinase KIT (also known as CD117 and SCFR) [22] [23] [24] [25] [26] . Recently, a clonogenic progenitor downstream of CDPs with prominent pDC potential has been reported 27 . This progenitor is LIN -KIT mid/low FLT3 + IL-7Rα -and does not express M-CSFR. It expresses high levels of E2-2 (also known as TCF4), the transcription factor that defines pDC lineage 28 , and can be derived from CDPs under conditions in which E2-2 is upregulated: that is, following exposure to M-CSF or thrombopoietin. A subsequent step in pDC development is the generation of a CCR9 -pDC-like common DC precursor that expresses some of the phenotypic markers of mature pDCs -such as CD11c, B220 and Siglec-H -but has low or negligible levels of MHC class II and CCR9. This CCR9 -pDC-like common DC precursor retains the potential to differentiate into either pDCs or cDCs, depending on the tissue environment 29, 30 . Therefore, the conversion of progenitors into pDCs or cDCs may happen not only at the CDP stage of development but also at a stage closer to terminal pDC differentiation.
Although many studies have focused on pDC differentiation within the myeloid lineage, there is also evidence that pDCs can originate from the lymphoid lineage. progenitor with prominent pDC potential described above 27 , which can subsequently differentiate into mature pDCs that either express or lack recombination-activating gene 1 (RAG1). pDCs of lymphoid origin may be distinct from pDCs of myeloid origin, but it has been reported that + T cells, as well as the polarization of CD4 + T cells into T helper 1 (T H 1) cells. pDC expression of indoleamine 2,3-dioxygenase (IDO) and inducible T cell co-stimulator ligand (ICOSL) and pDC production of transforming growth factor-β (TGFβ) and IL-6 promote regulatory T (T Reg ) cell or T H 17 cell commitment, respectively. Crosstalk between pDCs and invariant NKT (iNKT) cells occurs via OX40-OX40L (also known as TNFRSF4-TNFSF4) and programmed cell death protein 1 (PD1)-PD1 ligand 1 (PDL1) interactions and dampens antiviral adaptive immune responses. pDCs influence B cell activation, plasma cell generation and antibody secretion through production of type I IFNs, IL-6, B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL). TNF-related apoptosis inducing ligand (TRAIL) and granzyme B serve as immunoregulatory factors that endow pDCs with the capacity to kill tumour cells, induce apoptosis of infected CD4
+ T cells and suppress T cell proliferation. Finally, pDCs secrete chemokines such CXC-chemokine ligand 8 (CXCL8), CXCL10, CC-chemokine ligand 3 (CCL3) and CCL4, which attract immune cells to sites of infection or inflammation.
both lymphoid-and myeloid-derived pDCs can activate lymphoid-specific genetic programmes 31 such as nonproductive rearrangements of immunoglobulin or T cell receptor (TCR) genes and expression of pre-TCRα [32] [33] [34] . FLT3 and its ligand (FLT3L) are crucial for pDC development 35 . In the absence of FLT3 signalling, pDCs are reduced in number in the lymphoid organs and bone marrow of mice 36, 37 . FLT3L promotes pDC development through activation of signal transducer and activator of transcription 3 (STAT3) and phosphoinositide 3-kinase (PI3K)-dependent activation of mammalian target of rapamycin (mTOR) 38, 39 . Late endosomal/lysosomal adaptor and MAPK and mTOR activator 2 (LAMTOR2) is a component of the Ragulator complex that is known to inhibit mTOR signalling. Conditional deletion of Lamtor2 in CD11c + cells (which include cDCs and pDCs) causes accumulation of FLT3 on the cell surface and massive expansion of pDC and cDC populations in older mice 40 . Recently, it was shown that FLT3L and type I IFNs act synergistically to promote pDC development from common lymphoid progenitors by inducing upregulation of FLT3 (REF. 41 ). In addition to FLT3 signalling, macrophage colony stimulating factor (M-CSF; encoded by Csf1) may support the generation of pDCs 42 . Indeed, pDCs can be derived from M-CSFR + CDPs 23, 27 , and Csf1
-/-mice have reduced numbers of both pDCs and cDCs 43 . By contrast, the growth factor granulocytemacrophage colony-stimulating factor (GM-CSF) inhibits FLT3L-driven pDC development 44 . GM-CSF-induced STAT5 signalling abolishes pDC-related gene expression in FLT3 + progenitors and inhibits the transcription factor IFN-regulatory factor 8 (IRF8), which is crucial for pDC development, as discussed below 45 . E2-2 expression guides pDC differentiation. E2-2 is the transcription factor essential for committing CDPs to the pDC lineage in both mice and humans 28, 46 (FIG. 2) .
E2-2 and the transcription factors E12, E47 and HEB (also known as TCF12) make up the E family of class I basic helix-loop-helix transcription factors 47 . E proteins form homodimers or heterodimers with each other and bind to conserved E box sequences, a process that can be perturbed by inhibitor of DNA binding (ID) proteins. E2-2 binds to a large proportion of pDC-enriched genes, and continuous expression of E2-2 in pDCs is required to maintain cell fate 28, 48 . Deletion of E2-2 in mature pDCs causes the loss of pDC-associated markers, spontaneous differentiation into cDC-like cells, upregulation of MHC class II molecules and ultimately, an increase in the ability to prime T cells 48 . These cDClike cells are similar to the steady-state non-canonical CX 3 C-chemokine receptor 1 (CX 3 CR1) +
CD8α
+ DC population that is related to pDCs 49 . CX 3 CR1 + CD8α + DCs require E2-2 for their development, harbour immunoglobulin heavy chain (IgH) DJ gene rearrangements and are enriched for pDC-specific genes; however, they do not produce type I IFNs in response to influenza virus, and they lack surface expression of classical pDC markers such as B220 and BST2. Thus, non-canonical CX 3 CR1 + CD8α + DCs may represent an alternative fate of pDC-committed cells that are unable to reach or maintain high enough levels of E2-2 expression.
ID2, a repressor of E2-2, is essentially absent in pDCs but is prominently expressed in cDCs and supports CD8α + DC development from CDPs 28, 50 . pDC numbers are increased in Id2 -/-mice 50 , whereas overexpression of ID2 or ID3 inhibits pDC development in vitro 51 . STAT3 and STAT5 help to regulate the balance between E and ID proteins during DC development by controlling the expression of E2-2 and ID2, respectively 52 . STAT3 stimulates FLT3L-dependent expression of E2-2, whereas STAT5 induces GM-CSF-dependent expression of ID2 (FIG. 2) . A recent study also identified a transcriptional cofactor of the ETO family, MTG16 (also known as CBFA2T3), as a key factor that represses ID2, thereby driving pDC differentiation and restricting cDC development 53 (FIG. 2) .
Transcription factors targeted by E2-2. Transcriptional targets of E2-2 in pDCs encode proteins that are involved in the development, homeostasis and function of pDCs, including the transcription factors SPIB, B cell lymphoma 11A (BCL-11A), IRF8, Runt-related transcription factor 2 (RUNX2) and class II transactivator (CIITA); the cell surface markers BDCA2, ILT7 and Siglec-H; and the nucleic acid sensors TLR7, TLR9 and PACSIN1 (protein kinase C and casein kinase substrate in neurons protein) 28, 48, 54 (FIG. 2) .
Box 1 | Heterogeneity of mouse pDCs in the bone marrow CC-chemokine receptor 9 (CCR9), SCA1 and LY49Q are expressed by the majority of peripheral mouse plasmacytoid DCs (pDCs). However, in the bone marrow these markers can be used to discriminate pDC subsets that differ in their degree of maturation and their capacity to produce type I interferons (IFNs) . Two pDC subsets have been defined by CD9 expression 219 . The CD9 + subset has a high capacity for producing type I IFNs and stimulating T cell activation, and it may partially overlap with the non-plasmacytoid, high type I IFN-producing DC subset that has been described in the bone marrow 220 and with CCR9 − pDC-like common DC precursors. In general, studies on bone marrow pDC subsets suggest that newly generated pDCs or their close precursors may be more efficient at producing type I IFNs than mature pDCs in the bone marrow and in the periphery, at least in response to TLR agonists. However, it has also been reported that pDCs in the periphery, and not those in the bone marrow, are the major source of type I IFNs in mice infected with murine cytomegalovirus (MCMV) 221 . Most likely, the relative importance of bone marrow versus peripheral pDCs as sources of type I IFNs depends not only on their intrinsic capacity but also on the degree of exposure to viruses or other stimuli that elicit a type I IFN response.
In conclusion, pDC subsets in the bone marrow reflect different stages of development and/or activation and differ in their capacity to produce type I IFNs versus pro-inflammatory cytokines, as well as in their impact on T cell activation and T cell effector or regulatory functions. Clonogenic assays and consistency among gating strategies and markers used to define pDCs will be essential to determine which populations contain mature pDCs versus those that are heterogeneous and can give rise to different subsets.
SPIB is a transcription factor that is crucial for the differentiation of haematopoietic progenitors into pDCs, and it controls the survival of pDCs and their progenitors through induction of the anti-apoptotic gene BCL2-A1 . pDC numbers are reduced in the bone marrow of Spib -/-mice but are increased in the periphery, suggesting impaired retention in the bone marrow 59 . Furthermore, Spib -/-pDCs exhibit attenuated expression of pDC-specific genes and display defects in type I IFN production following TLR7 or TLR9 stimulation 59 . SPIB was also recently shown to be a novel immuno histochemical marker for the identification of human blastic pDC neoplasms 56 . 63 . Loss of pDCs, cDCs and monocytes in an individual with an IRF8 mutation that impairs DNA binding and transactivation has also been reported 64 . RUNX2 is a Runt family transcription factor that is required for the expression of several pDC-enriched genes including those encoding the chemokine receptors CCR2 and CCR5 (REF. 65 ). Mature pDCs in Runx2 -/-mice accumulate in the bone marrow and fail to populate peripheral compartments owing to reduced CCR5 expression. Additional transcription factors enriched in pDCs have been identified 54, 66 , but their roles in pDC development, maintenance and activation have not yet been characterized. Other regulators of pDC development, including microRNAs, are discussed in BOX 2.
In conclusion, although E2-2 is the master transcription factor for pDC development, it is becoming clear that E2-2 is a component of a multiprotein complex that includes both positive and negative regulators. More studies are required to define the various components of this complex as well as the genomic regions that interact with this complex and drive the expression of molecules that define pDC phenotype and function.
Trafficking of pDCs
Initial studies showed that pDC migration is quite different from that of cDCs. Following their development in the bone marrow, pDCs circulate in the blood and reach T cell areas of the lymph nodes mainly through high endothelial venules (HEVs) and not through afferent lymphatics 67, 68 . In addition to secondary lymphoid organs, pDCs also migrate from blood into peripheral tissues. pDC migration involves CD62L, P-selectin glycoprotein ligand 1 (PSGL1), β1 and β2 integrins, and multiple chemokine receptors such as CXCR3, CXCR4, CCR2, CCR5, CCR6, CCR7, CCR9 and CCR10 (REFS 68, 69) (FIG. 3) .
CXCR4 is required for the retention of pDCs in the bone marrow stromal niche and for their development 70 . CXCR4 and CCR7 mediate the migration of pDCs into the splenic white pulp 71 . CXCR4 also promotes pDC recruitment to tumours that produce CXCL12 (REF. 72 ). During inflammation, CXCR3 and CCR5 drive pDC migration to inflamed tissues 73, 74 . CCR2, which is expressed with a bimodal distribution on pDCs 65 , drives recruitment of pDCs to the skin following inflammation induced by topical application of imiquimod 75 . CCR6 and CCR10 are expressed by a subset of pDCs in human tonsils and facilitate migration into inflamed epithelial Nature Reviews | Immunology By contrast, granulocyte-macrophage colony-stimulating factor (GM-CSF)-STAT5 signalling blocks pDC differentiation during DC development by inducing the expression of inhibitor of DNA binding 2 (ID2), which is an antagonist of E2-2. The transcriptional cofactor MTG16 promotes pDC differentiation and restricts cDC development in part by repressing the expression of ID2. Transcriptional targets of E2-2 encode proteins associated with pDC development, homeostasis and function. SPIB, B cell lymphoma 11A (BCL-11A) and interferon-regulatory factor 8 (IRF8) are necessary for pDC differentiation and/or survival, whereas Runt-related transcription factor 2 (RUNX2) controls pDC homeostasis by inducing the expression of CC-chemokine receptor 2 (CCR2) and CCR5, which permit egress from the bone marrow. Class II transactivator (CIITA) promotes MHC class II expression. BDCA2, immunoglobulin-like transcript 7 (ILT7) and Siglec-H are markers that are selectively expressed by human or mouse pDCs, and they are involved in regulation of type I interferon (IFN) production. Toll-like receptor 7 (TLR7), TLR9 and PACSIN1 (protein kinase C and casein kinase substrate in neurons protein) enable pDC recognition of nucleic acids and pathogens (that is, RNA and DNA viruses), resulting in type I IFN secretion and/or pro-inflammatory cytokine production.
surfaces in response to CCL20 and CCL27 (REF. 76 ). pDC recruitment to the thymus and small intestine requires CCR9 (REFS 77, 78) , whereas pDC migration into the colon is CCR9 independent 79 . Mucosal addressin cell adhesion molecule 1 (MADCAM1) and β7 integrin were recently shown to promote pDC trafficking into the intestinal intraepithelial compartment 80 . pDCs can also migrate in response to the engagement of receptors for chemerin (ChemR23) and adenosine, as well as C3a and C5a, which are released at sites of tissue damage 68 . CX 3 CR1 is expressed by pDCs; however, its role in pDC migration and homeostasis is not well characterized.
Several recent studies have identified intracellular proteins that selectively affect pDC trafficking in the steady state and in disease conditions. Human and mouse pDCs express CD2-associated protein (CD2AP) 81 , an intracellular protein that regulates actin dynamics and promotes pDC migration to lymph nodes during inflammation 82 . DOCK2, a haematopoietic cell-specific member of the CDM (Caenorhabditis elegans Ced-5, mammalian DOCK180 and Drosophila melanogaster myoblast city) family of proteins, is necessary for migration of pDCs to lymph nodes and to the peri-arteriolar lymphoid sheaths of the spleen 83 . Chemokine-induced RAC activation is severely impaired in Dock2 -/-pDCs, resulting in reduced motility and the loss of polarity during chemotaxis 83 .
Innate sensing by pDCs Sensing of pathogens and self nucleic acids by TLR7 and TLR9. The recognition of viruses or self nucleic acids by pDCs is mainly mediated by TLR7 and TLR9, which are located in endosomal compartments. Activation of these receptors in pDCs results in their secretion of type I IFNs via the myeloid differentiation primary response protein 88 (MYD88)-IRF7 pathway, as well as their production of pro-inflammatory cytokines and chemokines via the MYD88-nuclear factor-κB (NF-κB) pathway (reviewed in REFS 6-8). TLR7 senses RNA viruses, endogenous RNA and synthetic oligoribonucleotides, whereas TLR9 detects DNA viruses containing unmethylated CpG-rich DNA sequences, endogenous DNA and synthetic CpG oligodeoxyribonucleotides. As pDCs constitutively express high levels of IRF7 and produce type I IFNs 84 , they are largely resistant to viral infection unless type I IFN signalling is compromised 85 . Therefore, uptake and recognition of viral nucleic acids by pDCs probably occurs via mechanisms that are independent of viral infection. Such mechanisms are not yet completely understood and are the subject of intensive investigation. In the case of hepa titis A virus, virions coated in host membrane enter pDCs through the phosphatidylserine receptor T cell immunoglobulin and mucin domain-containing 1 (TIM1; also known as HAVCR1) 86 , whereas pDCs sense hepatitis C virus (HCV) via exosomes containing HCV-derived RNAs that are released from infected cells 87 . Direct contact of pDCs with vesicular stomatitis virus (VSV)-infected cells triggers type I IFN production in a manner that is TLR dependent and more robust than that triggered by free virus alone 88 . Viruses and endogenous nucleic acids can enter pDCs through Fc receptors when bound by antibodies during an immune response. Recently, it was documented that the inhibitory Fc receptor FcγRIIB promotes the uptake of Sendai virus immune complexes during a memory response and prevents type I IFN production by pDCs 89 . By contrast, endo genous nucleic acids are internalized as a complex with antinuclear antibodies via the activating Fc receptor FcγRIIA [90] [91] [92] .
Box 2 | Additional regulators of pDC development
Other transcriptional regulators are involved in plasmacytoid dendritic cell (pDC) development, including IKAROS, PU.1, X box-binding protein 1 (XBP1), hypoxia-inducible factor 1α (HIF1α), growth factor independent 1 (GFI1) and nuclear polyadenylated RNA-binding protein 2 (NAB2). Mice that express low levels of IKAROS lack peripheral pDCs, but not other DC subsets, and are impaired in their ability to produce type I interferons (IFNs) in response to Toll-like receptor 7 (TLR7) or TLR9 ligands 222 . PU.1 directly regulates Fms-like tyrosine kinase (FLT3) expression in a concentration-dependent manner and is necessary for both pDC and classical DC (cDC) development 223 . XBP1 is a target of the unfolded protein response sensor IRE-1α that maintains endoplasmic reticulum (ER) homeostasis and prevents the activation of cell death pathways 224 . XBP1 deficiency results in impaired survival and reduced numbers of pDCs and cDCs 225 . Treatment of pDCs with the proteasome inhibitor bortezomib reduces levels of the active form of XBP1 and suppresses pDC survival and immunostimulatory functions by targeting ER homeostasis and the intracellular trafficking of TLRs 226 . Hypoxia-inducible factors influence haematopoiesis and maintain haematopoietic stem cell function. Recently, it was shown that low oxygen content upregulates the expression of inhibitor of DNA binding 2 (ID2) and suppresses FLT3 ligand (FLT3L)-induced pDC development, in a manner dependent on HIF1α 227 . GFI1 controls the development and functions of pDCs and cDCs in a signal transducer and activator of transcription 3 (STAT3)-dependent manner 228 and represses recombination-activating gene (Rag) transcription in pDCs 229 . NAB2 is a transcriptional co-repressor that induces TNF-related apoptosis-inducing ligand (TRAIL) expression in activated pDCs 230 . TRAIL-expressing pDCs are tumoricidal 231 and induce apoptosis of CD4 + T cells in patients with viraemic HIV or after exposure to human T lymphotropic virus 1 (HTLV1) [232] [233] [234] . MicroRNAs represent another class of regulatory molecules that control different aspects of pDC development and function. miR-22 is induced in progenitor cultures by granulocyte-macrophage colony-stimulating factor (GM-CSF) and it targets Irf8 mRNA (which encodes IFN-regulatory factor 8) for post-transcriptional repression 235 . Overexpression of miR-22 during DC development promotes the expansion of CD11b + cDC populations at the expense of pDCs. Epigenetic or chromatin modifiers may also have a prominent role in DC lineage commitment and development. In support of this, histone deacetylation is required for PU.1 recruitment to target genes (including Flt3, Irf8 and PU.1 itself) and for pDC differentiation from progenitors 236 .
Whether engagement of TLR7 or TLR9 results in the production of type I IFN or pro-inflammatory cytokines depends on the type of compartment in which these TLRs encounter their ligands 93, 94 (FIG. 4) .
Multimeric CpG-A oligonucleotides aggregate in early endosomes where they activate the MYD88-IRF7 pathway that induces type I IFNs. By contrast, monomeric CpG-B is transferred to an endolysosomal compartment where it activates the MYD88-NF-κB pathway that triggers the expression of co-stimulatory molecules and the secretion of pro-inflammatory cytokines. IκB kinase-α (IKKα) 95 , osteopontin 96 and mTOR 97 are key components of the MYD88-IRF7 signalling pathway, whereas IRF5 is essential for MYD88-NF-κB signalling 98, 99 . Trafficking of TLR9 to the subcellular compartment for type I IFN production is dependent on adaptor protein 3 (AP3), as virus-or CpG-induced type I IFN expression is abolished in the absence of AP3 (REFS 100,101). Forward genetic approaches have further identified Slc15a4 (which encodes the peptide/ histidine transporter 1 (PHT1)) and the BLOC1 and BLOC2 Hermansky-Pudlak syndrome proteins as key components required for TLR9 signalling in pDCs but not in other cell types 101 . However, TLR9-mediated recognition of large DNA-containing immune complexes is independent of AP3 (REF. 102 ) and requires the convergence of phagocytic and autophagic pathways. This process is called microtubule-associated protein 1A/1B-light chain 3 (LC3)-associated phagocytosis (LAP) and involves autophagy-related proteins but not the conventional autophagic pre-initiation complex. Recognition of live, single-stranded RNA (ssRNA) viruses by TLR7 in pDCs also occurs in a distinct subcellular compartment that requires the transport of cytosolic viral replication intermediates into the lysosome by autophagy 103 . Several additional molecules involved in TLR7 and TLR9 signalling have been identified in pDCs. The scavenger receptor SCARB2 (also known as LIMP2) is highly expressed in pDCs and regulates TLR9-dependent type I IFN production by mediating TLR9 endosomal translocation and IRF7 nuclear translocation 104 . Phospholipid scramblase 1 (PLSCR1) is a TLR9-interacting protein that regulates TLR9 trafficking to endosomal compartments and type I IFN production in pDCs 105 . PACSIN1 is an endocytic adaptor specifically expressed in mouse and human pDCs that is essential for TLR9-induced type I IFN secretion but not pro-inflammatory cytokine production 54, 106 . Viperin (also known as RSAD2) is an IFN-inducible antiviral protein that promotes TLR7 and TLR9 signalling in pDCs by recruiting IL-1 receptor-associated kinase 1 (IRAK1) and TNF receptorassociated factor 6 (TRAF6) to lipid bodies and by inducing nuclear translocation of IRF7 (REF. 107 ). In addition to having a role in pDC migration, DOCK2 is essential for TLR7-and TLR9-mediated type I IFN production in pDCs, most likely because of its influence on the actin cytoskeleton and vesicular trafficking 108 . In the absence of DOCK2, phosphorylation of IKKα and nuclear translocation of IRF7 are impaired in pDCs, but the capacity to produce pro-inflammatory cytokines is maintained. TLR9, but not TLR7, signalling is also dependent on Bruton's tyrosine kinase (BTK) 109 . Blocking BTK inhibits all TLR9-induced responses in pDCs, including cytokine production and the expression of co-stimulatory molecules. Additional studies are required to provide an integrated view of how all of these molecules coordinate the trafficking and signalling properties of TLR7-and TLR9-containing vesicles in pDCs.
TLR2-and TLR12-mediated sensing in pDCs. Although TLR7 and TLR9 are important for pDC-mediated detection of viruses and self nucleic acids, recent evidence indicates that mouse pDCs also express TLR12 and TLR2, which permit detection of Toxoplasma gondii profilin 110 and bacterial polysaccharide A (PSA) 111 , respectively. Although TLR11 and TLR12 can both express chemokine receptors and homing molecules that promote recruitment in the steady state and during inflammation. Development of pDCs in the bone marrow stromal cell niche requires CXC-chemokine receptor 4 (CXCR4) expression, whereas pDC egress from the bone marrow into the blood is dependent on CC-chemokine receptor 2 (CCR2) and CCR5. pDCs are attracted to tumours that produce CXC-chemokine ligand 12 (CXCL12; not shown) and the splenic white pulp via CXCR4. DOCK2, a haematopoietic cell-specific CDM family protein involved in CXCR4 signalling, is also necessary for pDC migration to the spleen and lymph nodes. pDCs express CD62L, P-selectin glycoprotein ligand 1 (PSGL1), β1and β2 integrins, and the chemokine receptors CCR5, CXCR3 and CCR7, which enables their adhesion and chemotaxis to peripheral lymph nodes and the splenic white pulp under normal and/or inflammatory conditions. Blood pDCs express the chemerin receptor, ChemR23, as well as adenosine receptor A1 and complement receptors C3aR and C5aR, which may guide them to peripheral lymph nodes and damaged tissues. CD2-associated protein (CD2AP) is an intracellular protein that regulates actin dynamics and promotes pDC migration to lymph nodes under inflammatory settings. CCR2 drives the recruitment of pDCs to the skin following inflammation induced by the Toll-like receptor 7 (TLR7) agonist imiquimod. CCR6 and CCR10 are expressed by a subset of human tonsil pDCs and enable migration to inflamed epithelia producing CCL20 and CCL27 (not shown). CCR9 and its ligand CCL25 (not shown) promote trafficking of peripheral pDCs to the thymus and are required for pDC recruitment to the small intestine under both normal and inflammatory conditions. Mucosal addressin cell adhesion molecule 1 (MADCAM1), β7 integrin and CD103 also influence pDC trafficking to the gut. Finally, pDCs express CX 3 C-chemokine receptor 1 (CX 3 CR1; not shown), which may affect their homeostasis. 
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Figure 4 | Toll-like receptor 9 signalling in pDCs. Plasmacytoid dendritic cells (pDCs) sense DNA viruses, synthetic CpG oligodeoxyribonucleotides (ODNs) and endogenous DNA molecules through Toll-like receptor 9 (TLR9). All TLR9 signalling requires myeloid differentiation primary response protein 88 (MYD88), but additional factors determine whether TLR9 engagement will result in the production of type I interferons (IFNs) or pro-inflammatory cytokines. These factors include the mode of ligand entry and the intracellular compartment in which TLR9 encounters its ligand. TLR9 is transported to appropriate intracellular compartments by UNC93B1 (REFS 249, 250) and requires cleavage in order to recruit MYD88 (REFS 251, 252) . DNA viruses, CpG ODNs and small DNA immune complexes (DNA-ICs) enter pDCs through endocytosis and encounter TLR9 in the early endosome. By contrast, large DNA-ICs are internalized by phagocytosis and encounter TLR9 and UNC93B1 in the early phagosome. If adaptor protein 3 (AP3) or microtubule-associated protein 1A/1B-light chain 3 (LC3) are recruited then the IFN-regulatory factor 7 (IRF7) endosome or IRF7 phagosome is formed, which leads to type I IFN production. Several molecules and pathways are involved in this process including IκB kinase-α (IKKα), osteopontin (OPN), SLC15A4, Bruton's tyrosine kinase (BTK), BLOC1, BLOC2, DOCK2, PACSIN1 (protein kinase C and casein kinase substrate in neurons protein), phospholipid scramblase 1 (PLSCR1), viperin, SCARB2 and the mammalian target of rapamycin (mTOR) pathway. Alternatively, TLR9-containing compartments can form nuclear factor-κB (NF-κB) endosomes or NF-κB phagosomes, resulting in the production of pro-inflammatory cytokines and chemokines (such as interleukin-6 (IL-6), IL-12 and tumour necrosis factor (TNF)). This process requires IRF5, BTK and SLC15A4. CpG ODNs have different structures (not shown) that result in trafficking to different compartments: CpG-A is transported to the IRF7 endosome and is a strong inducer of type I IFNs, whereas CpG-B aggregates in the NF-κB endosome and is a potent stimulator of maturation and the production of cytokines and chemokines. CpG-C exhibits properties of both CpG-A and CpG-B in that it can induce both type I IFNs and pro-inflammatory cytokines. TLR7 stimulation by viral and endogenous RNAs may follow similar pathways.
Star-form partner
The less abundant of the two strands of microRNA (miRNA) that are generated during miRNA biogenesis. Star-form mi RNAs may have important functions in miRNA regulatory networks.
cytokine production by pDCs has just begun to be explored. CpG-A oligonucleotides selectively bind to the (DExD/H)-box helicase DHX36, and this is associated with the nuclear translocation of IRF7 and type I IFN production in pDCs 113 . By contrast, CpG-B oligonucleotides are bound by DHX9, and this results in NF-κB activation and the secretion of pro-inflammatory cytokines in pDCs. Additionally, in the absence of type I IFN signalling, viruses can replicate in pDCs, producing viral nucleic acid that can be detected in a retinoic acid-inducible gene I (RIG-I)-like helicase-dependent manner 85 . Major cytosolic sensors of nucleic acids, such as cGMP-AMP synthase (cGAS) and stimulator of IFN genes protein (STING) 114 , are also likely to be investigated in pDCs in the near future.
Regulation of TLR7 and TLR9 responses in pDCs
Regulatory receptors expressed by pDCs. Human and mouse pDCs express cell surface receptors that control the amplitude of type I IFN production and pDC activation state in response to TLR7 or TLR9 ligands 115 . Many of these receptors either contain intracellular tyrosine-based inhibitory motifs (ITIMs) or they deliver intracellular signals through an associated adaptor, usually DNAX activation protein 12 (DAP12; also known as TYROBP) or the γ-chain of Fc receptors (FcRγ), which have an intracellular tyrosine-based activation motif (ITAM 126 and EBI2 (also known as GPR183) 127 .
Regulation by microRNAs and hormones. MicroRNAs and hormones can also affect TLR7 and TLR9 signalling and pDC functions. Expression of miR-146a is induced upon engagement of TLR7 and TLR9, and this suppresses NF-κB activation and TLR-mediated signalling in pDCs 128 . miR-155 and its star-form partner miR-155* are expressed in pDCs after TLR7 signalling and have opposing effects on type I IFN production 129 . Shortly after TLR7 stimulation, miR-155* is induced and augments type I IFN expression by inhibiting IRAKM (also known as IRAK3), whereas miR-155 induction occurs later and shuts down type I IFN production by targeting TAB2 (TGFβ-activated kinase 1 and MAP3K7-binding protein 2). miR-126 has a prominent role in promoting the survival and function of pDCs 130 . miR-126 targets the mTOR pathway and regulates the expression of genes including Tlr7, Tlr9, Nfkb1 and Kdr (which encodes the growth factor receptor VEGFR2). The homeostasis of pDCs and their capacity to respond to TLR ligands are impaired in both miR-126 -/-and Kdr -/-mice, indicating a role for VEGFR2 in supporting type I IFN production 130 . Recently, it was shown that TLR7-mediated signalling in pDCs is enhanced by oestrogen 131 . Notably, this would provide a mechanistic basis for the observation that pDCs from women produce more type I IFN in response to HIV than pDCs from men 132 .
pDCs as antigen-presenting cells As pDCs express MHC class II molecules and the co-stimulatory molecules CD40, CD80 and CD86, they can present antigens to CD4 + T cells, albeit not as efficiently as cDCs (reviewed in REFS 133, 134) . Antigen presentation by pDCs can lead to CD4 + T cell activation or tolerance induction, depending on the context (FIG. 1) . When pDCs receive activation signals through TLRs or other pattern recognition receptors, they act as immunogenic cells. When pDCs are either unstimulated or alternatively activated -such that they express indoleamine 2,3-dioxygenase (IDO) [135] [136] [137] [138] , ICOSL 139 , OX40L (also known as TNFSF4) 140 , programmed cell death protein 1 ligand 1 (PDL1) 141 and/or granzyme B 142 -they promote tolerance to tumour cells, alloantigens and harmless antigens.
Recent studies have proposed that pDCs that capture antigens in peripheral tissues use CCR9 to migrate to the thymus where they induce deletion of antigen-specific thymocytes, contributing to immune tolerance 77 . It has also been reported that CCR9 + pDCs are potent inducers of regulatory T (T Reg ) cell function and can inhibit acute graft-versus-host disease induced by allogeneic CD4 + donor T cells in irradiated recipients 143 . This study defined pDCs as being either B220 + CD11c + CCR9 + or B220 + CD11c + CCR9 -, the former being the tolerogenic subset; however, a later study provided evidence that B220 + CD11c + CCR9 -cells are not a subset of pDCs but rather are precursors of lymphoid tissue-resident cDCs 144 . In a mouse model of lung inflammation, adoptive transfer of CD8α + pDCs suppressed the development of airway hyper-reactivity by inducing T Reg cells 145 ; however, it has been reported that CD8 subunit expression by mouse pDCs is variable and does not define stable subsets 146 . Corroborating this, earlier studies found that CD8α is expressed by only a proportion of pDCs in steady-state conditions but is induced in the majority of pDCs after activation 9, 147 . Thus, the role of pDC subsets in tolerance remains to be further explored.
To selectively examine pDC antigen presentation capacity, antigens have been specifically targeted to pDCs by conjugating them to antibodies specific for pDC cell surface molecules. A recent study found that targeting antigens to BDCA2 promotes immunological tolerance by suppressing antigen-specific CD4 + T cell and antibody responses upon secondary exposure to antigen in the presence of adjuvant, a process that involves both preservation of T Reg cells and a decrease in the number of effector CD4 + T cells 148 . Antigens targeted to pDCs through DCIR are also presented to T cells 120 . In mice, it was shown that targeting a T cell epitope derived from
Non-canonical NF-κB pathway
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myelin oligodendrocyte glycoprotein (MOG) to pDCs via Siglec-H delays the onset and decreases the severity of disease in a model of MOG-induced experimental autoimmune encephalomyelitis (EAE) by reducing the expansion and polarization of T helper 1 (T H 1) and T H 17 cell populations 149 . By contrast, antigen delivery to pDCs via BST2 in combination with TLR agonists generates robust cellular and humoral immunity and protects mice against subsequent viral infection or tumour growth 150 . Thus, targeting antigen to pDCs can either promote or inhibit antigen-specific immune responses, depending on the antigen formulation and the mode of stimulation or delivery.
In mouse models, pDCs have mostly been studied for their effect on antigen presentation to CD4 + T cells, but human studies have focused on pDC antigen presentation to CD8 + T cells 151, 152 . Human pDCs have recycling endosomes in which peptides can be continuously loaded on to MHC class I molecules, and this enables efficient presentation of viral antigens to CD8 + T cells 153 . Through this mechanism, pDCs may contribute to adaptive responses during viral infections.
pDCs as a source of type I IFNs in viral infections Acute viral infections. Type I IFN production by pDCs in response to acute viral infections is usually limited in time and amplitude (reviewed in REF. 154 ). pDC secretion of type I IFNs is most evident at early time-points in systemic infections with viruses such as murine cytomegalovirus (MCMV), VSV, lymphocytic choriomeningitis virus (LCMV) and herpes simplex virus 1 (HSV1) and mediates an immediate containment of viral replication. However, pDC-derived IFNs becomes less important later on in the infection as other host cells become more dominant producers of type I IFNs. The impact of pDCs also depends on the route of infection. pDCs provide an important source of type I IFNs in systemic infections, when the virus reaches the circulation. By contrast, the requirement for pDCs in type I IFN-mediated antiviral defence during local viral infections seems to be necessary only if other lines of defence are broken. For example, in pulmonary infection with Newcastle disease virus (NDV), alveolar macrophages are the primary source of type I IFNs, and if they are eliminated then pDC-derived type I IFNs become important 155 . Only in the case of mouse hepatitis virus (MHV) and HSV2 infections have pDC-derived type I IFNs been shown to be critical for viral control in mice, reducing both morbidity and mortality [156] [157] [158] . A recent study found that individuals carrying inactivating mutations in IRF7 have a severe defect in pDC function and are selectively susceptible to influenza virus infections 159 . It remains to be determined whether the pDC defect is sufficient to cause susceptibility to influenza or if IRF7 has a more general impact on the capacity of all cells to respond to the virus. Paradoxically, pDC responses to acute viral infections may not always be beneficial. Recent evidence indicates that excessive production of type I IFNs, probably by pDCs, during influenza virus infection in 129 mice can result in uncontrolled inflammation and apoptosis of bronchial epithelium that is mediated by TNF-related apoptosis-inducing ligand (TRAIL; also known as TNFSF10) 160 . Thus, the impact of pDCs on acute viral infections may vary considerably depending on the virus, the route of infection and the genetic background.
Chronic viral infections.
The role of pDCs in chronic viral infections, such as HIV-1, is even more complex, involving pDC activation, trafficking, type I IFN production and interaction with CD4 + T cells (reviewed in REF. 161 ). HIV induces pDC activation through TLR7 but can also directly infect pDCs as they express CD4, CXCR4 and CCR5, which are co-receptors for viral entry. HIV promotes pDC trafficking to peripheral lymph nodes, and this is reflected by the reduced numbers of pDCs found in the blood of patients with HIV 162 . Moreover, new evidence indicates that pDCs upregulate the gut-homing markers α4β7 integrin and CD103 and accumulate in the gut mucosa during simian immunodeficiency virus (SIV) and HIV infections 162, 163 . Interestingly, pDCs from elite controllers also maintain a gut-homing phenotype, suggesting that gut trafficking of pDCs is independent of viral load 164 . pDCs may contribute to the chronicity of HIV infection through dysregulated activation and type I IFN production (reviewed in REF. 165 ). HIV-stimulated pDCs express low levels of maturation molecules, induce weak T cell responses and persistently secrete type I IFNs, due to HIV trafficking to early endosomes 166 . In addition, HIV-stimulated pDCs produce chemokines and express TRAIL, thereby promoting recruitment and apoptosis of T cells. HIV can also activate the non-canonical NF-κB pathway in pDCs, resulting in the expression of IDO and the induction of T Reg cells 167 . Non-canonical NF-κB signalling and induction of a tolerogenic pathway in pDCs stimulated with high doses of CpG have also been reported 168 . Studies in humanized mice have shown that depletion of pDCs before or during chronic HIV-1 infection severely reduces type I IFN production and increases viral replication 169 . However, HIV-1-induced CD4 + T cell death is curbed despite elevated viral loads, suggesting that pDCs suppress HIV-1 replication but also contribute to HIV-1 immunopathogenesis. Conversely, studies in SIV infection have provided a different view. Blockade of TLR7-and TLR9-mediated IFNα production by pDCs did not diminish immune activation during SIV infection 170 , suggesting that other sources of type I IFNs may contribute to immunopathology.
The beneficial or detrimental effects of pDCs and type I IFNs in chronic viral infections may also depend on the timing of their action. During SIV infection, the timing of type I IFN production has a marked effect on the disease course 171 . Exogenous administration of IFNα2a early on augments the expression of antiviral genes and prevents systemic infection; however, sustained IFNα2a treatment induces type I IFN desensitization, decreases antiviral gene expression, increases viral load and accelerates CD4 + T cell loss. In mice, constitutive absence of pDCs or loss of their ability to signal through TLR7 and TLR9 in chronic LCMV infection seems to have a negative effect on T cell priming and viral clearance 157, 172 .
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Moreover, early administration of exogenous type I IFN prevents chronic LCMV infection. However, late type I IFN administration has no beneficial effects 173 . In fact, blockade of type I IFN signalling during chronic LCMV infection improves T cell function and diminishes viral persistence 174, 175 . Thus, there is a window of opportunity -that is, early during infection -when type I IFNs and pDCs can be both beneficial and necessary to prevent or control chronic viral infection and preserve T cell numbers and functions.
Pathogenic functions of pDCs in autoimmunity Role of pDCs in systemic lupus erythematosus. pDCs have been implicated in the pathogenesis of autoimmune diseases that are characterized by a type I IFN signature, such as systemic lupus erythema tosus (SLE; reviewed in REF. 176 ). In SLE, antinuclear antibodies form immune complexes with endogenous nucleic acids, which are delivered to pDC endosomal compartments via the Fc receptor CD32, where they activate TLR7 and TLR9 . This process is enhanced by high-mobility group box 1 (HMGB1) 177 . Neutrophils have been proposed to be a prominent source of endogenous nucleic acids for activation of pDCs in SLE. After exposure to ribonucleoproteinspecific antibodies, neutrophils release extracellular traps (NETs) containing chromatin DNA, the antimicrobial peptide LL-37 (also known as CAMP) and HMGB1, which trigger the TLR9 pathway in pDCs, resulting in type I IFN secretion 178, 179 . Counter to this hypothesis, lupus-prone MRL.Fas lpr mice have markedly exacerbated lupus when crossed with mice lacking NADPH oxidase (NOX2), such that neutrophils are incapable of forming NETs 180 . Thus, endogenous nucleic acids that stimulate pDCs in SLE may be derived from other modes of cell death, such as necroptosis or pyroptosis, as well as from NADPH-independent release of mitochondrial DNA 181 . Sustained activation of pDCs is also detrimental in SLE because it results in the resistance of pDCs to therapeutic glucocorticoids, which are often administered to patients with SLE to control inflammation 182, 183 . Bioinformatics and functional analyses have suggested that TLR activation prevents glucocorticoid-induced pDC apoptosis by inhibiting miR-29b and miR-29c, which promote pDC apoptosis by targeting MCL1 and BCL-2 (REF. 184 ). Endogenous glucocorticoids also influence pDC homeostasis and survival 185 . Regulation of endogenous glucocorticoid concentrations involves the conversion of inactive substrates to active 11-hydroxyglucocorticoids by an enzyme complex containing 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and hexose-6-phosphate dehydrogenase (H6PDH). Under physiological conditions, 11βHSD1-H6PDH increases the sensitivity of pDCs to glucocorticoid-induced apoptosis. However, following activation with TLR ligands, the effects of enzyme activity are overridden.
Studies in various rodent models of SLE have confirmed that type I IFNs and pDCs contribute to disease pathogenesis. Male mice of the BXSB lupusprone strain have a duplication of Tlr7 and develop spontaneous autoimmunity. Blockade of type I IFN signalling early on in these mice reduces disease manifestations and extends survival 186 . Disruption of type I IFN signalling in MRL.Fas lpr mice also provides some therapeutic benefit; however, it does not affect mortality. In addition, autoimmune skin inflammation induced by tape stripping in lupus-prone (NZB×NZW) F1 mice is ameliorated by antibody-mediated pDC depletion or by blocking TLR7 and TLR9 signalling with a bifunctional inhibitor 187 . Genetic models that specifically address the contribution of pDCs in autoimmunity have been lacking until recently. Deletion of Irf8 in NZB mice and a mutation in Slc15a4 in C57BL/6.Fas lpr mice abolish production of autoantibodies and disease manifestations 188 . Although this study provides compelling evidence that pDCs and their TLR7-or TLR9-mediated responses are damaging in SLE, IRF8 and SLC15A4 are not exclusively expressed by pDCs. In fact, B cell expression of SLC15A4 seems to be necessary for TLR7-induced expression of type I IFNs and pathogenic antibody production in a mouse model of lupus 189 . Analysis of MRL.Fas lpr mice lacking MYD88 have shown that MYD88-dependent production of IFNα by pDCs contributes to SLE pathogenesis, particularly to B lymphopenia, but not to nephritis 190 . Two recent studies using lupus-prone mice that specifically lack pDCs have confirmed that pDCs are pathogenic in SLE. Global or CD11c-specific E2-2 haplodeficiency in lupus-prone mice nearly abolishes autoantibody production and glomerulonephritis 191 , whereas transient depletion of pDCs before disease initiation in BXSB mice impairs the expansion and activation of B cells and T cells, and reduces the levels of antinuclear antibodies and the expression of type I IFN-induced genes in tissues 192 . Taken together, these studies validate pDCs as a therapeutic target in SLE.
pDCs in other autoimmune diseases. Chronic activation of pDCs and dysregulated type I IFN production also seem to be contributing factors in initiating and/or promoting psoriasis and type 1 diabetes (T1D). In psoriasis, self nucleic acids form complexes with antimicrobial peptides that activate pDCs through TLR7 and TLR9 [193] [194] [195] . Interestingly, the vitamin D analogue calcipotriol, which is used to treat psoriatic skin lesions, triggers tolerogenic responses in cDCs and was recently shown to impair the capacity of both human and mouse pDCs to induce T cell proliferation and effector T cell differentiation 196 . In the non-obese diabetic (NOD) mouse model of T1D, activated B1a cells produce DNAreactive antibodies that stimulate release of LL-37 from neutrophils; LL-37 subsequently binds to self DNA and activates pDCs through TLR9 (REF. 197 ).
The deleterious roles of pDCs in psoriasis and T1D have not yet been confirmed in genetic models, but blockade of type I IFNs or antibody-mediated depletion of pDCs seems to confer protection in mouse models of these diseases [197] [198] [199] . Future studies will be necessary to address whether blockade of type I IFNs or depletion of pDCs are potential therapeutic avenues for intervention in psoriasis and T1D in humans.
Gut-associated pDCs
As mucosal immunity and microbiome research is rapidly progressing, pDCs that reside within gut and gutassociated lymphoid tissues are also becoming the focus of increasing interest. In the 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis model, PSA-induced protection is highly dependent on the ability of pDCs to induce the generation of IL-10-producing T Reg cells 111 . pDCs from the liver and mesenteric lymph nodes are also important for suppression of T cell responses and induction of oral tolerance 200 . In contrast to splenic pDCs, pDCs from Peyer's patches are unable to produce type I IFNs after TLR7 or TLR9 stimulation 201 . pDCs that have been developed in the presence of type I IFN resemble Peyer's patch pDCs, produce pro-inflammatory cytokines, stimulate T H 17 cell generation and fail to secrete IFNα after TLR engagement 202 . Therefore, factors expressed at mucosal sites inhibit type I IFN secretion by pDCs, but they do not block the ability of pDCs to prime naive T cells and trigger T Reg and T H 17 cell differentiation 203, 204 . Gut-associated pDCs are also efficient at generating mucosal B cell responses under normal conditions and during infection with a gut-tropic virus. In the steady state, pDCs from Peyer's patches and mesenteric lymph nodes induce T cell-independent IgA production 205 . Specifically, the microbiota activates stromal cells to produce type I IFNs, which drive pDC expression of B cellactivating factor (BAFF; also known as TNFSF13B) and a proliferation-inducing ligand (APRIL; also known as TNFSF13), which facilitate IgA responses in the gut. Viral clearance and protection against reinfection with rotavirus, an intestinal pathogen, is highly dependent on B cells 206 . Type I IFN production by human and mouse pDCs exposed to rotavirus seems to be necessary for B cell activation, virus-specific antibody secretion and viral clearance during infection 206 . How the microbiota influences pDC functions is largely unknown, but one study found that colonization of the intestine with a restricted microflora resulted in the lysis of pDCs by activated cytotoxic T lymphocytes 207 . Therefore, specific microbial communities are likely to have a marked influence on pDC homeostasis and function through both direct and indirect mechanisms.
Concluding remarks
Although many immune functions of pDCs have now been described, many questions still remain concerning their complex biology. Tuberculosis in humans is associated with a type I IFN signature 208 and pDC accumulation in lymph nodes 209 . So what is the role of pDCs in tuberculosis and in bacterial infections in general? Can bacterial products activate pDCs, and what are the sensors for these products? Although pDCs accumulate in the microenvironment of some tumours, they are reduced in other cancers such as chronic lymphocytic leukaemia 210 . What is the impact of pDCs in antitumour immune responses, and can we exploit these cells to generate effective T cell responses
Although SLE is generally associated with a type I IFN signature, it has recently been shown that pDC production of type I IFNs is impaired in patients carrying a variant of PTPN22 (non-receptor tyrosine-protein phosphatase type 22) that predisposes to SLE 211 . This observation raises the question of whether pDC and type I IFN depletion is a valid strategy for all SLE patients or whether it should be adopted after stratification of the patients for pDC activity. Recent studies suggest that pDC dysfunction in autoimmune and inflammatory diseases may extend to scleroderma 212 , Sjögren syndrome 213 , Wiskott-Aldrich syndrome 214 and atherosclerosis 215 . Is there a role for pDCs in other inflammatory diseases such as inflammatory bowel disease? Is manipulation or elimination of pDCs a feasible therapeutic strategy for some of these diseases? Whether pDCs are valid targets during viral infections remains a matter of debate.
Box 3 | pDCs and cancer
The recruitment of plasmacytoid dendritic cells (pDCs) to tumours is often associated with poor prognosis, as tumour-infiltrating pDCs tend to be tolerogenic rather than immunogenic. Unstimulated or alternatively activated pDCs can induce regulatory T (T Reg ) cells through expression of indoleamine 2,3-dioxygenase (IDO) [135] [136] [137] [138] or inducible T cell co-stimulator ligand (ICOSL) 139 . The accumulation of IDO-expressing cells in tumour-draining lymph nodes has been associated with worse clinical outcomes in patients with malignant tumours, including those with breast carcinoma 137 . The infiltration of pDCs in primary tumours of patients with invasive non-metastatic breast cancer correlates with shorter survival times, suggesting that pDCs contribute to the progression of breast cancer 237 . Breast tumour-associated pDCs are poor producers of type I interferons (IFNs) and favour the expansion of T Reg cells 238 . The mechanisms suppressing type I IFN production and the immunogenic capacity of breast tumourinfiltrating pDCs include tumour cell-derived transforming growth factor-β (TGFβ) and tumour necrosis factor (TNF) 239 ; both TGFβ and TNF inhibit type I IFN secretion by pDCs 201, 240 . ICOSL expression on pDCs also seems to correlate with breast cancer progression by supporting amplification of interleukin-10 (IL-10)-producing T Reg cells 241 . Recruitment of pDCs to ovarian tumours is driven by CXC-chemokine ligand 12 (CXCL12) and is associated with impaired T cell responses and poor prognosis 72, 242 . Compared with pDCs in blood or ascites, ovarian tumour-associated pDCs produce lower levels of type I IFNs and pro-inflammatory cytokines and chemokines in response to Toll-like receptor (TLR) stimulation, and they induce IL-10 production from allogeneic naive CD4 + T cells. This suggests that they have a crucial role in the induction of immune tolerance and in the progression of ovarian cancer 243 . Human pDCs may also contribute to cancer progression via the production and release of the pro-apoptotic molecule granzyme B
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, which suppresses T cell proliferation. Activation of pDCs through TLR agonists and CD40 ligand negatively regulates granzyme B expression and the ability of pDCs to suppress T cells 142 . In contrast to natural killer (NK) cells, pDCs do not release the pore-forming protein perforin and therefore are unable to kill target tumour cells by releasing lytic granules.
However, pDCs can also promote immunogenic antitumour responses if appropriately stimulated. Injection of activated pDCs loaded with tumour-associated peptides into patients with metastatic melanoma leads to favourable CD4 + and CD8 + T cell responses, indicating that vaccination strategies using activated pDCs might be an attractive therapeutic strategy to overcome immune tolerance in certain types of cancer 244 . In an orthotopic murine mammary tumour model, intratumoural administration of a TLR7 ligand results in tumour-associated pDC activation and has a potent antitumour effect 245 . In the B16 melanoma mouse model, TLR-stimulated pDCs mediate tumour killing through expression of TNF-related apoptosis-inducing ligand (TRAIL) and granzyme B 75 , as well as through the activation of NK cells 246 . The ability of pDCs to produce cytolytic mediators and the functional relevance of this capacity in the elimination of target cells and immune regulation has been extensively debated; however, it has been shown that the FSME-IMMUN vaccine (Baxter) against tick-borne encephalitis stimulates pDCs to upregulate their expression of neural cell adhesion molecule 1 (NCAM1; also known as CD56) and TRAIL, thereby generating a subset of pDCs that combines the abilities of type I IFN production and antigen presentation with that of lysing target cells 247 . NCAM1 expression is also typical of several neoplastic human pDC tumours 248 .
Although pDC activation may be beneficial at early stages of infection, depletion of pDCs may be considered during chronic viral infections, such as HIV, when type I IFNs may exert negative effects.
Addressing these and other questions in mouse models will require advanced tools to deplete pDCs in vivo. The development of transgenic mice expressing the diphtheria toxin receptor under the control of the Bdca2 promoter (Bdca2-DTR mice) has provided a method for specific but transient pDC depletion 216 . Conditional targeting of E2-2 in CD11c + cells has enabled constitutive depletion of pDCs 157 , although CX 3 CR1 + CD8α + DCs 49 (which are closely related to pDCs) and possibly B cell subsets expressing CD11c may also be affected. It will be important to continue to identify pDC-specific genes that can be used for development of pDC lineage-specific deficient mice and pDC-specific Cre deleters. With the recognition of pDC involvement in human pathologies, it is predicted that these cells will be more extensively evaluated for diagnostic and prognostic purposes. Indeed, it will be interesting to explore the therapeutic potential of monoclonal antibodies that selectively target pDCs in many of the disease scenarios discussed above.
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